Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Secukinumab in active lupus nephritis
NCT04181762Phase 3Terminated
- Sponsor
- Novartis
- Start
- Jul 2020
- Primary completion
- Sep 2023
- Modality
- Monoclonal Antibodies
- Countries
- 34
01
Overview
A Phase 3 trial of secukinumab in lupus nephritis (LN), sponsored by Novartis. Started Jul 2020; status: terminated.
02
Drugs
secukinumab
03
Conditions
lupus nephritis (LN)
Beyond the preview
Go deeper on NCT04181762.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04181762.